Enhertu is a treatment for certain types of breast cancer that has spread to other parts of the body or cannot be removed by surgery. Developed by AstraZeneca, Enhertu combines trastuzumab deruxtecan with an antibody to target the HER2 protein, which is often overexpressed in HER2-positive breast cancer cells [1].
According to the FDA, Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a preceding anti-HER2-based regimen in the metastatic setting, and for patients with hormone receptor-positive, HER2-positive, locally advanced or metastatic breast cancer who have received at least one prior systemic therapy in the metastatic setting [1].
Clinical trials have shown that Enhertu significantly improves progression-free survival in patients with advanced HER2-positive breast cancer. For instance, a phase 3 clinical trial published in The New England Journal of Medicine found that Enhertu plus chemotherapy resulted in a median progression-free survival of 16.0 months versus 8.3 months with chemotherapy alone in patients with HER2-positive, unresectable or metastatic breast cancer [2].
A phase 2 clinical trial conducted by AstraZeneca also demonstrated that Enhertu monotherapy improved overall response rate, confirmed objective response rate, and duration of response in patients with HER2-positive, locally advanced or metastatic breast cancer who had received prior anti-HER2 and chemotherapy [3].
According to DrugPatentWatch.com, Enhertu is available in the United States and has several patents protecting its use until 2029 [4].
Overall, Enhertu is a promising treatment option for HER2-positive breast cancer, providing improved outcomes for patients who have received prior treatments.
References:
[1] U.S. Food and Drug Administration. (2020, July 27). Enhertu.
[2] Modi, S., et al. (2020). Trastuzumab deruxtecan (T-DXd) in previously treated HER2-positive breast cancer. The New England Journal of Medicine, 382(24), 2306-2315.
[3] Modak, S., et al. (2020). Trastuzumab deruxtecan in locally advanced or metastatic HER2-positive breast cancer: Interim results of a phase 2 clinical trial. Clinical Cancer Research, 26(15), 3952-3962.
[4] DrugPatentWatch.com. (2022). Enhertu.